451 related articles for article (PubMed ID: 21694603)
21. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Mulu A; Maier M; Liebert UG
PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
[TBL] [Abstract][Full Text] [Related]
22. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
23. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
[TBL] [Abstract][Full Text] [Related]
24. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
[TBL] [Abstract][Full Text] [Related]
25. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
[TBL] [Abstract][Full Text] [Related]
26. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
27. Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China.
Zhao Y; Mu W; Harwell J; Zhou H; Sun X; Cheng Y; Li C; Zhang F
J Acquir Immune Defic Syndr; 2011 Sep; 58(1):47-53. PubMed ID: 21725248
[TBL] [Abstract][Full Text] [Related]
28. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment.
Kouamou V; Varyani B; Shamu T; Mapangisana T; Chimbetete C; Mudzviti T; Manasa J; Katzenstein D
AIDS Res Hum Retroviruses; 2020 Jul; 36(7):566-573. PubMed ID: 32138527
[TBL] [Abstract][Full Text] [Related]
29. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
30. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.
Etiebet MA; Shepherd J; Nowak RG; Charurat M; Chang H; Ajayi S; Elegba O; Ndembi N; Abimiku A; Carr JK; Eyzaguirre LM; Blattner WA
AIDS; 2013 Feb; 27(4):553-61. PubMed ID: 23079810
[TBL] [Abstract][Full Text] [Related]
32. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
[TBL] [Abstract][Full Text] [Related]
33. High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.
Segujja F; Omooja J; Lunkuse S; Nanyonjo M; Nabirye SE; Nassolo F; Bugembe DL; Bbosa N; Kateete DP; Ssenyonga W; Mayanja Y; Nsubuga RN; Seeley J; Kaleebu P; Ssemwanga D
AIDS Res Hum Retroviruses; 2020 Sep; 36(9):782-791. PubMed ID: 32475121
[TBL] [Abstract][Full Text] [Related]
34. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
35. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Jittamala P; Puthanakit T; Chaiinseeard S; Sirisanthana V
Pediatr Infect Dis J; 2009 Sep; 28(9):826-30. PubMed ID: 19654564
[TBL] [Abstract][Full Text] [Related]
36. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W;
Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461
[TBL] [Abstract][Full Text] [Related]
37. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
[TBL] [Abstract][Full Text] [Related]
38. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Tang MW; Rhee SY; Bertagnolio S; Ford N; Holmes S; Sigaloff KC; Hamers RL; de Wit TF; Fleury HJ; Kanki PJ; Ruxrungtham K; Hawkins CA; Wallis CL; Stevens W; van Zyl GU; Manosuthi W; Hosseinipour MC; Ngo-Giang-Huong N; Belec L; Peeters M; Aghokeng A; Bunupuradah T; Burda S; Cane P; Cappelli G; Charpentier C; Dagnra AY; Deshpande AK; El-Katib Z; Eshleman SH; Fokam J; Gody JC; Katzenstein D; Koyalta DD; Kumwenda JJ; Lallemant M; Lynen L; Marconi VC; Margot NA; Moussa S; Ndung'u T; Nyambi PN; Orrell C; Schapiro JM; Schuurman R; Sirivichayakul S; Smith D; Zolfo M; Jordan MR; Shafer RW
J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S70-7. PubMed ID: 23687292
[TBL] [Abstract][Full Text] [Related]
39. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
40. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
Hosseinipour MC; van Oosterhout JJ; Weigel R; Phiri S; Kamwendo D; Parkin N; Fiscus SA; Nelson JA; Eron JJ; Kumwenda J
AIDS; 2009 Jun; 23(9):1127-34. PubMed ID: 19417582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
